At the Myeloma 2015 meeting, Dr Bruno Paiva (University of Navarra, Spain) discusses the utility of flow cytometry as a therapeutic tool to identify precursor cells and detect the presence or absence of minimal residue disease (MRD) in multiple myeloma.